Fidrisertib (IPN60130) for Treating Fibrodysplasia Ossificans Progressiva: A Patient's Guide

What is Fidrisertib?

Fidrisertib, also known as IPN60130, is an experimental medication being developed to treat a rare genetic condition called Fibrodysplasia Ossificans Progressiva (FOP). The scientific name for this drug is (R)‑tetrahydrofuran‑3‑yl 4‑(6‑(5‑(4‑ethoxy‑1‑isopropylpiperidin‑4‑yl)pyridin-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate. It comes in the form of hard capsules that are taken by mouth.1

What is Fibrodysplasia Ossificans Progressiva (FOP)?

Fibrodysplasia Ossificans Progressiva (FOP) is a very rare and serious genetic disorder. In this condition, the body's soft tissues (like muscles, tendons, and ligaments) gradually turn into bone over time. This process is called heterotopic ossification (HO). FOP can severely limit a person's movement and cause significant pain and disability.1

How Fidrisertib Works

While the exact mechanism is not fully explained in the provided information, Fidrisertib is designed to target the underlying cause of FOP. It aims to inhibit or slow down the process of heterotopic ossification, potentially preventing new bone formation in soft tissues.1

Current Clinical Trial

Fidrisertib is currently being studied in a Phase 2 clinical trial. This trial is designed to evaluate how well the drug works (its efficacy) and how safe it is when used to treat both children and adults with FOP. The study will compare two different dosing regimens of Fidrisertib against a placebo (a substance with no active medication).1

Who Can Participate in the Trial?

The trial is open to both male and female patients with FOP, including children and adults. Here are some key eligibility criteria:

• Participants must be at least 5 years old (younger children may be included later in the study)
• Must have a clinical diagnosis of FOP with a specific genetic mutation (R206H ACVR1 or other FOP variants)
• Must have shown disease progression in the year before screening
• Must weigh at least 10 kg (about 22 pounds)
• Must be able to undergo certain medical tests without sedation

There are also several factors that might prevent someone from participating, such as certain heart conditions, liver problems, or use of specific medications.1

What the Trial Aims to Achieve

The main goals of this clinical trial are:

1. To see if Fidrisertib can slow down or stop new bone formation in soft tissues (heterotopic ossification) compared to placebo
2. To evaluate how safe Fidrisertib is for people with FOP

The researchers will use special low-dose whole-body CT scans to measure new bone formation. They will also look at other factors such as:

• The number of disease flare-ups
• Changes in pain levels
• Effects on joint movement
• Impact on overall physical function

These measurements will help determine how effective Fidrisertib is in managing FOP symptoms and progression.1

Potential Benefits of Fidrisertib

While it's important to note that the benefits of Fidrisertib are still being studied, the researchers hope that it might:

• Reduce the formation of new bone in soft tissues
• Decrease the number and severity of disease flare-ups
• Improve or maintain joint movement
• Reduce pain associated with FOP
• Improve overall physical function and quality of life for people with FOP

However, these potential benefits are not guaranteed and will be carefully evaluated during the clinical trial.1

Safety Considerations

As with any experimental treatment, there may be risks and side effects associated with Fidrisertib. The clinical trial will closely monitor participants for any adverse effects. Some areas of particular focus include:

• Heart function (through ECGs and echocardiograms)
• Liver function
• Blood cell counts
• Eye health
• Overall physical health

Participants in the trial will have regular check-ups and tests to ensure their safety throughout the study period.1